NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: NATCOPHARM · data 2026-10-30
NATCO Pharma Limited
In plain words
Price: 35.7% below its 52-week high of ₹1,217.06.
Delivery: 54.6% of traded shares were kept for delivery over the last 10 sessions, against 51.5% over the last 60.
Latest results: a net profit of ₹207 cr for the quarter ended Jun 2026 (-57.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹3,485 cr |
| Net profit (last 12 months) | ₹1,144 cr |
| Sales growth, 3 years (yearly) | 14.5% |
| Profit growth, 3 years (yearly) | 25.6% |
Latest results in brief (Q1 FY27)
NATCOPHARM Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹735.2 crore, down 44.7% YoY and down 0.5% QoQ.
Net profit was ₹206.5 crore, down 57% YoY and down 22.9% QoQ.
Operating margin was 25.4% (43% a year ago).
EPS was ₹11.53, down 57% YoY and down 22.9% QoQ.
NATCOPHARM के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹735.2 करोड़; पिछले साल की तुलना में 44.7% की गिरावट, पिछली तिमाही की तुलना में 0.5% की गिरावट।
शुद्ध मुनाफ़ा: ₹206.5 करोड़; पिछले साल की तुलना में 57% की गिरावट, पिछली तिमाही की तुलना में 22.9% की गिरावट।
ऑपरेटिंग मार्जिन: 25.4% (एक साल पहले 43%)।
EPS: ₹11.53; पिछले साल की तुलना में 57% की गिरावट, पिछली तिमाही की तुलना में 22.9% की गिरावट।
NATCOPHARMના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹735.2 કરોડ; ગયા વર્ષની સરખામણીએ 44.7% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 0.5% ઘટાડો.
ચોખ્ખો નફો: ₹206.5 કરોડ; ગયા વર્ષની સરખામણીએ 57% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 22.9% ઘટાડો.
ઓપરેટિંગ માર્જિન: 25.4% (એક વર્ષ પહેલાં 43%).
EPS: ₹11.53; ગયા વર્ષની સરખામણીએ 57% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 22.9% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
24/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 13/30: Delivery 55.6% over the last 20 sessions vs 45.2% in the 40 before (1.23x); shares delivered per day 1.21x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 5/15: 5 schemes hold it, about ₹20 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 1/15: Verdict "None", sustained score 31/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Rights ● Dividend ● Results
- 1 Oct 26Rights Rights issue 2:21 · premium ₹748 (ex-date) -0.7% next session
- 20 Aug 26Dividend Dividend ₹1.5 (ex-date) -0.5% next session
- 14 Aug 26Results Q1 FY27 results: profit −57.0% YoY -6.5% next session
- 29 May 26Results Q4 FY26 results: profit −34.1% YoY -20.6% next session
- 18 Feb 26Dividend Dividend ₹1.5 (ex-date) +0.4% next session
- 12 Feb 26Results Q3 FY26 results: profit +13.9% YoY -3.2% next session
- 20 Nov 25Dividend Dividend ₹1.5 (ex-date) +4.2% next session
- 14 Nov 25Results Q2 FY26 results: profit −23.5% YoY -0.6% next session
- 19 Aug 25Dividend Dividend ₹2 (ex-date) +1.6% next session
- 12 Aug 25Results Q1 FY26 results: profit −28.1% YoY +0.5% next session
- 28 May 25Results Q4 FY25 results: profit +5.3% YoY +1.7% next session
- 18 Feb 25Dividend Dividend ₹1.5 (ex-date) -6.6% next session
- 12 Feb 25Results Q3 FY25 results: profit −37.5% YoY -21.5% next session
- 27 Nov 24Dividend Dividend ₹1.5 (ex-date) -1.3% next session
- 12 Nov 24Results Q2 FY25 results: profit +83.6% YoY -2.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹735 cr | ₹207 cr | -57.0% | 25.4% | 11.53 |
| Mar 2026 | ₹739 cr | ₹268 cr | -34.1% | 17.3% | 14.96 |
| Dec 2025 | ₹647 cr | ₹152 cr | +13.9% | 24.5% | 8.46 |
| Sept 2025 | ₹1,363 cr | ₹518 cr | -23.5% | 42.5% | 28.94 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 49.39% | 49.42% | 49.42% | 49.48% |
| Foreign institutions (FII) | 16.00% | 16.99% | 17.37% | 15.16% |
| Domestic institutions (DII) | 6.16% | 5.62% | 5.46% | 5.39% |
| Mutual funds | 2.25% | 1.92% | 1.72% | 1.60% |
| Retail investors | 20.64% | 20.16% | 20.13% | 21.99% |
| Number of shareholders | 4,04,135 | 4,03,166 | 4,10,970 | 4,24,167 |
Common questions
What was NATCO Pharma Limited's latest quarterly profit?
NATCO Pharma Limited reported a net profit of ₹207 cr for the quarter ended Jun 2026 (-57.0% on the same quarter a year earlier), on revenue of ₹735 cr.
How much do promoters hold in NATCO Pharma Limited?
Promoters held 49.39% of NATCO Pharma Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is NATCO Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0.08, which is very low.
What is NATCO Pharma Limited's P/E ratio?
About 12.4, based on the last 12 months' earnings and a price of ₹782.4 (data 2026-10-30).
What is the 52-week high and low of NATCO Pharma Limited?
The 52-week high is ₹1,217.06 and the 52-week low is ₹773.6.
Mutual funds holding NATCO Pharma Limited
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 5 schemes holding about ₹20 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND | Aditya Birla Sun Life Mutual Fund | 0.92% | ₹10 cr |
| Mirae Asset Nifty Smallcap 250 Momentum Quality 100 ETF | Mirae Asset Mutual Fund | 0.70% | ₹7 cr |
| ADITYA BIRLA SUN LIFE NIFTY SMALLCAP 50 INDEX FUND | Aditya Birla Sun Life Mutual Fund | 0.87% | ₹3 cr |
| Nippon India Nifty 500 Quality 50 Index Fund | Nippon India Mutual Fund | 0.97% | ₹0 cr |
| Mirae Asset Nifty 500 Healthcare ETF | Mirae Asset Mutual Fund | 0.55% | ₹0 cr |
Similar companies
Eris Lifesciences Ltd (ERIS) · AstraZeneca Pharma India Limited (ASTRAZEN) · Alembic Pharmaceuticals Limited (APLLTD) · Jubilant Pharmova Limited (JUBLPHARMA) · Indegene Limited (INDGN)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open NATCOPHARM in NSE Scanner →